<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04222985</url>
  </required_header>
  <id_info>
    <org_study_id>HSV15</org_study_id>
    <secondary_id>U1111-1183-6522</secondary_id>
    <nct_id>NCT04222985</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2</brief_title>
  <acronym>HSV15</acronym>
  <official_title>Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults With Recurrent Genital Herpes Caused by HSV 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Design</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are:

        -  To describe the safety profile of different investigational vaccine regimens against
           herpes simplex virus type 2 (HSV-2).

        -  To evaluate the efficacy of the investigational vaccine regimens with respect to:

        -  the frequency of herpes simplex virus (HSV) deoxyribonucleic acid (DNA) detection in the
           genital area (shedding rate) following a 2 dose vaccine schedule

        -  the proportion of participants free of HSV genital recurrence at 6 months after the
           2-dose vaccine schedule

      The secondary objectives of the study are:

        -  To describe the impact of each of the investigational vaccine regimens in terms of total
           number of days with genital lesion up to 6 months after vaccination 2 and number of
           recurrences 60 days after the second vaccination compared with the placebo group

        -  To describe the efficacy of each of the investigational vaccine regimens with respect to
           the frequency of HSV DNA detection in the genital area (shedding rate) 60 days following
           the first vaccination visit plus 60 days following the second vaccination visit compared
           with the placebo group

        -  To describe the efficacy of each of the investigational vaccine regimens with respect to
           the frequency of HSV DNA detection in the genital area (shedding rate) 60 days following
           the first vaccination visit compared with the placebo group
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is approximately 16 months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with immediate adverse events</measure>
    <time_frame>Within 4 hours (participants in Part A) or 30 minutes (participants in Part B) after vaccination</time_frame>
    <description>Unsolicited systemic adverse events occurring immediately after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with solicited injection site and systemic reactions</measure>
    <time_frame>Within 7 days after vaccination</time_frame>
    <description>Injection site reactions: injection site pain, erythema, and swelling. Systemic reactions: fever, headache, malaise, myalgia, arthralgia and chills</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with unsolicited adverse events</measure>
    <time_frame>Within 30 days after vaccination</time_frame>
    <description>An unsolicited adverse event is an event that does not fulfill the conditions prelisted in the Case Report Book in terms of diagnosis and/or onset post-vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with medically-attended adverse events (MAAEs)</measure>
    <time_frame>From Day 0 to Month 14</time_frame>
    <description>An MAAE is a new onset or a worsening of a condition that prompts the participant to seek unplanned medical advice at a physician's office or Emergency Department</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events of special interest (AESIs)</measure>
    <time_frame>From Day 0 to Month 14</time_frame>
    <description>AESIs are collected throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with serious adverse events (SAEs)</measure>
    <time_frame>From Screening to Month 14</time_frame>
    <description>SAEs are collected throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with out-of-range biological test results</measure>
    <time_frame>From Day 8 to Day 30</time_frame>
    <description>Out-of-range biological test results area assessed at Days 8 and 30 after each vaccination and 15 days prior to second vaccination in Part A and Days 8 and 30 after each vaccination in Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral genital shedding rate</measure>
    <time_frame>60 days before first vaccination and 60 days after the second vaccination</time_frame>
    <description>Relative change in HSV DNA detection frequency between swabs collected before the first vaccination and those collected after the second vaccination visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genital HSV recurrence</measure>
    <time_frame>6 months following the second vaccination</time_frame>
    <description>Proportion of participants free of genital HSV recurrence following the second vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genital lesion rate</measure>
    <time_frame>6 months after the second vaccination</time_frame>
    <description>Total number of days that the participants who receive investigational product or placebo report genital herpes lesions following the second vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genital HSV recurrence</measure>
    <time_frame>60 days following the second vaccination</time_frame>
    <description>Number of recurrences of genital HSV following the second vaccination in participants who receive investigational product or placebo. Recurrence is defined as the appearance of genital and perineal lesions (i.e., shingles, blisters, ulcers) in a previously asymptomatic participant. Regarding 2 separate episodes of recurrences, recurrence is defined as the presentation of a new lesion (or lesions) after a 1-day-minimum (≥ 24 hours) lesion-free period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral genital shedding rate after the first and second vaccination</measure>
    <time_frame>60 days before first vaccination, and 60 days after the first vaccination, plus 60 days after the second vaccination</time_frame>
    <description>Relative change in HSV DNA detection frequency between swabs collected before the first vaccination visit and those collected 60 days after the first vaccination visit plus after the second vaccination visit in participants who receive investigational product or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral genital shedding rate after the first vaccination</measure>
    <time_frame>60 days before and 60 days after the first vaccination</time_frame>
    <description>Relative change in HSV DNA detection frequency between swabs collected before the first vaccination visit and those collected 60 days after the first vaccination visit in participants who receive investigational product or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum HSV 2-antibody levels</measure>
    <time_frame>Before and 30 days after the first and second vaccinations and 6 months after the second vaccination</time_frame>
    <description>Change between pre-vaccination and post-first and second vaccinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of HSV 2-specific cellular immune responses</measure>
    <time_frame>Before and 8 days after the first and second vaccination and 6 months after the second vaccination</time_frame>
    <description>Change between pre-vaccination and post-first and second vaccinations</description>
  </secondary_outcome>
  <number_of_arms>20</number_of_arms>
  <enrollment type="Anticipated">381</enrollment>
  <condition>Genital Herpes</condition>
  <arm_group>
    <arm_group_label>Part A - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Group 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium chloride 0.9% (in both arms) at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 1) - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 1) - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 1) - Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 1) - Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 1) - Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 1) - Group 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 1) - Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 2) - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 2) - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 2) - Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 2) - Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 2) - Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 2) - Group 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Stage 2) - Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSV 2 Formulation 1</intervention_name>
    <description>Route of administration: Intramuscular</description>
    <arm_group_label>Part A - Group 1</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 1</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSV 2 Formulation 2</intervention_name>
    <description>Route of administration: Intramuscular</description>
    <arm_group_label>Part A - Group 2</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 2</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSV 2 Formulation 3</intervention_name>
    <description>Route of administration: Intramuscular</description>
    <arm_group_label>Part A - Group 3</arm_group_label>
    <arm_group_label>Part A - Group 4</arm_group_label>
    <arm_group_label>Part A - Group 5</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 3</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 4</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 5</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 3</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 4</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSV 2 Formulation 4</intervention_name>
    <description>Route of administration: Intramuscular</description>
    <arm_group_label>Part A - Group 4</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 4</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSV 2 Formulation 5</intervention_name>
    <description>Route of administration: Intramuscular</description>
    <arm_group_label>Part A - Group 5</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 5</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSV 2 Formulation 6</intervention_name>
    <description>Route of administration: Intramuscular</description>
    <arm_group_label>Part B (Stage 1) - Group 7</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sodium Chloride 0.9%</intervention_name>
    <description>Route of administration: Intramuscular</description>
    <arm_group_label>Part A - Group 1</arm_group_label>
    <arm_group_label>Part A - Group 2</arm_group_label>
    <arm_group_label>Part A - Group 3</arm_group_label>
    <arm_group_label>Part A - Group 4</arm_group_label>
    <arm_group_label>Part A - Group 6</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 1</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 2</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 3</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 4</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 6</arm_group_label>
    <arm_group_label>Part B (Stage 1) - Group 7</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 1</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 2</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 3</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 4</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 6</arm_group_label>
    <arm_group_label>Part B (Stage 2) - Group 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Aged 18 to 55 years on the day of inclusion

          -  Informed consent form has been signed and dated

          -  Able to attend all scheduled visits and to comply with all trial procedures

          -  In good general health with absence of significant health problems as determined by
             medical history, physical examination, and laboratory screening performed during
             screening visits

          -  HSV-2 seropositive confirmed by Western blot

          -  A history of established HSV-2 infection ≥ 1 year

          -  A history of at least 2 and no more than 9 reported HSV clinical recurrences in the
             prior 12 months, or, if currently on suppressive therapy, history of at least 2 and no
             more than 9 reported clinical recurrences in the 12 months prior to initiation
             suppressive therapy

          -  For Part A and Part B, the participant is willing to refrain from using suppressive
             antiviral therapy starting 5 days before the first vaccination visit and up to 6
             months after the second vaccination visit; and for Part B, throughout the 3, 60-day
             swabbing periods, and up to 6 months after the second vaccination visit

          -  For Part A and Part B, the participant is willing to refrain from using antiviral
             therapy to treat recurrences starting 5 days before V01 and up to 6 months after the
             second vaccination visit; and for Part B, throughout the 3, 60-day swabbing periods
             (i.e., up to 60 days after the second vaccination visit)

        Exclusion criteria:

          -  For Part A, the participant is pregnant, or lactating, or of childbearing potential
             and not using an effective method of contraception or abstinence from at least 4 weeks
             prior to the first vaccination until at least 6 months after the last vaccination. To
             be considered of non-childbearing potential, a female must be post-menopausal for at
             least 1 year, or surgically sterile.

          -  For Part B, the participant is pregnant, or lactating, or of childbearing potential
             and not using an effective method of contraception or abstinence with her/his partner
             from at least 4 weeks before the enrollment visit until at least 6 months after the
             last vaccination. To be considered of non-childbearing potential, a female must be
             post-menopausal for at least 1 year, or surgically sterile.

          -  Participants whose female partners are pregnant at the time of enrollment or plan to
             become pregnant between study entry through 12 weeks (for Part A) and 6 months (for
             Part B) after the second vaccination visit.

          -  Participation at the time of study enrollment (or in the 4 weeks preceding the first
             trial vaccination) or planned participation during the present trial period in another
             clinical trial investigating a vaccine, drug, medical device, or medical procedure

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily

          -  Receipt of any vaccine in the 4 weeks preceding the first study vaccination or planned
             receipt of any vaccine in the 4 weeks before and/or following any trial vaccination
             except for influenza vaccination, which may be received at a gap of at least 2 weeks
             before or 2 weeks after any study vaccination

          -  Current alcohol abuse or drug addiction

          -  Positive serologic test or polymerase chain reaction for human immunodeficiency virus
             type 1 infection

          -  Positive hepatitis B surface antigen

          -  Positive antibody for hepatitis C virusribonucleic acid and positive hepatitis C test

          -  Severe active infection or serious HSV-2 related medical conditions on the day of
             enrollment that, in the opinion of the Investigator, would prevent study completion

          -  Active genital herpes determined by the presence of outbreaks (genital lesions) at the
             time of enrollment. A prospective subject should not be included in the trial until 24
             hours after the outbreak has resolved (the lesions have completely disappeared)

          -  Hemoglobin, white blood cell count with differential, platelet count, renal function
             tests (serum creatinine, blood urea nitrogen), liver function tests, creatine
             phosphokinase and C-reactive protein screening laboratory results that fall into the
             range of values that are Grade 2 or greater as per the study toxicity grading scale
             for this study. Also the range of values that are Grade 1 and are deemed clinically
             significant in the opinion of the Investigator (Grade 1 values deemed not clinically
             significant may be enrolled at the Investigator's discretion)

          -  Previous vaccination against HSV infection with either the trial vaccine or another
             vaccine against HSV

          -  History of HSV infection of the eye (e.g., herpes simplex interstitial keratitis or
             uveitis)

          -  History of eczema herpeticum

          -  History of herpes-associated erythema multiforme

          -  History of lesions caused by HSV on either arm

          -  History of any autoimmune disorder

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
             within the preceding 6 months; or long-term systemic corticosteroid therapy
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)

          -  Receipt of immune globulins, blood or blood-derived products in the past 3 months

          -  Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on
             Investigator's judgment

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccines used in the trial or to a vaccine containing
             any of the same substances

          -  Known allergy or intolerance to nickel

          -  Known allergy or intolerance to acyclovir or valacyclovir

          -  Identified as an Investigator or employee of the Investigator or study center with
             direct involvement in the proposed study, or identified as an immediate family member
             (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with
             direct involvement in the proposed study

          -  Chronic illness or other conditions that, in the opinion of the Investigator, is at a
             stage where it might interfere with trial conduct or completion

          -  Moderate or severe acute illness/infection (according to the Investigator's judgment)
             on the day of vaccination or febrile illness (temperature ≥ 100.4 °F ([≥ 38 °C]).

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400010</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400003</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400006</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

